JP2023526328A5 - - Google Patents

Info

Publication number
JP2023526328A5
JP2023526328A5 JP2022569509A JP2022569509A JP2023526328A5 JP 2023526328 A5 JP2023526328 A5 JP 2023526328A5 JP 2022569509 A JP2022569509 A JP 2022569509A JP 2022569509 A JP2022569509 A JP 2022569509A JP 2023526328 A5 JP2023526328 A5 JP 2023526328A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
riz2
composition according
sequence
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022569509A
Other languages
English (en)
Japanese (ja)
Other versions
JP7863050B2 (ja
JP2023526328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032311 external-priority patent/WO2021231771A2/en
Publication of JP2023526328A publication Critical patent/JP2023526328A/ja
Publication of JP2023526328A5 publication Critical patent/JP2023526328A5/ja
Application granted granted Critical
Publication of JP7863050B2 publication Critical patent/JP7863050B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022569509A 2020-05-14 2021-05-13 ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療 Active JP7863050B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024624P 2020-05-14 2020-05-14
US63/024,624 2020-05-14
PCT/US2021/032311 WO2021231771A2 (en) 2020-05-14 2021-05-13 CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN

Publications (3)

Publication Number Publication Date
JP2023526328A JP2023526328A (ja) 2023-06-21
JP2023526328A5 true JP2023526328A5 (enExample) 2024-05-17
JP7863050B2 JP7863050B2 (ja) 2026-05-20

Family

ID=78525067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569509A Active JP7863050B2 (ja) 2020-05-14 2021-05-13 ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療

Country Status (5)

Country Link
US (2) US12012597B2 (enExample)
EP (1) EP4150093A4 (enExample)
JP (1) JP7863050B2 (enExample)
CN (1) CN116113421A (enExample)
WO (1) WO2021231771A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7863050B2 (ja) 2020-05-14 2026-05-20 エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療
US20260224735A1 (en) * 2023-01-10 2026-08-06 Ariz Precision Medicine, Inc. Targeted anti-prdm compositions and uses thereof
CN119405814A (zh) * 2024-12-18 2025-02-11 青岛大学附属医院 Eno1作为靶点在制备治疗膀胱癌的药物组合物中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831008A (en) * 1994-08-18 1998-11-03 La Jolla Cancer Research Foundation Retinoblastoma protein-interacting zinc finger proteins
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
WO2002092002A2 (en) * 2001-05-11 2002-11-21 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7439208B2 (en) 2003-12-01 2008-10-21 Superconductor Technologies, Inc. Growth of in-situ thin films by reactive evaporation
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2005111238A2 (en) * 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
JP4352976B2 (ja) 2004-04-20 2009-10-28 株式会社日立製作所 受信装置及び受信方法
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
AU2005250464B2 (en) 2004-06-01 2010-10-07 The Penn State Research Foundation Unagglomerated core/shell nanocomposite particles
US8603991B2 (en) * 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
WO2008038832A1 (en) 2006-09-27 2008-04-03 Sapporo Medical University Therapeutic agent, detection method and detection kit for breast cancer and ovarian cancer
US8771741B2 (en) 2009-01-23 2014-07-08 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
WO2011050178A2 (en) 2009-10-21 2011-04-28 Lonnie Bookbinder Targeted prdm gene or protein modulation therapeutic agents
US9149544B2 (en) 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
JP6033218B2 (ja) 2010-05-21 2016-11-30 ペプティメド， インコーポレイテッド がんを治療するための試薬および方法
SG10201508981YA (en) 2010-11-01 2015-11-27 Peptimed Inc Compositions Of A Peptide-Based System For Cell-Specific Targeting
US10226424B2 (en) 2012-08-12 2019-03-12 Mylisa Parette Therapeutic calcium phosphate nanoparticle incorporating siRNA useful in treating disease
JP6683986B2 (ja) 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
CA2921005A1 (en) * 2013-08-16 2015-02-19 Ohio State Innovation Foundation Compositions and methods for modulating dna methylation
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
SG10201806064XA (en) 2014-08-27 2018-08-30 Peptimed Inc Anti-tumor compositions and methods
WO2016065273A1 (en) 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
EP3359167A4 (en) * 2015-10-09 2019-11-13 Children's Medical Center Corporation METHOD AND COMPOSITIONS FOR INCREASING HUMAN SOMATIC CELL CORE TRANSFER EFFICIENCY BY REMOVING HISTON-H3-LYSINE TRIMETHYLATION AND DERIVING FROM HUMAN NT-ESC
JP2022545055A (ja) 2019-07-09 2022-10-25 アライズ プレシジョン メディシン，インク． ＰＲＤＭ１４タンパク質の発現をダウンレギュレートする標的化ｓｉＲＮＡ製剤を使用する癌処置
JP7863050B2 (ja) 2020-05-14 2026-05-20 エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療

Similar Documents

Publication Publication Date Title
US10550391B2 (en) Organic compositions to treat beta-ENaC-related diseases
JP2022526419A (ja) 中枢神経系における遺伝子発現を阻害するための組成物及び方法
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
WO2023051822A1 (zh) 用于治疗与pcsk9相关疾病的靶向寡核苷酸
JP2023539341A5 (enExample)
US20220267775A1 (en) CANCER TREATMENT USING TARGETED siRNA PHARMACEUTICAL FORMULATIONS TO DOWNREGULATE EXPRESSION OF PRDM14 PROTEIN
CN114585633A (zh) 寡核苷酸缀合物组合物和使用方法
US20220143197A1 (en) siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer
US20240360445A1 (en) CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
JP2020532958A5 (enExample)
US11667920B2 (en) Methods for treating brain injury
Matsui et al. Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier
WO2017009837A1 (en) Micro-rna for the treatment of malignant solid tumors and metastasis
KR20260005402A (ko) 암 치료를 위한 조성물 및 방법
WO2025103391A1 (zh) 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
EP3902917A2 (en) Compositions and methods for treating cancer
WO2024073399A2 (en) Dna-affibody-drug nanostructures for inhibiting triple negative breast cancer growth and metastasis
WO2019107487A1 (ja) マイクロｒｎａ及びその誘導体を有効成分とする医薬組成物
CN112654706B (zh) 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途
HK40076806B (en) Cancer treatment using targeted sirna pharmaceutical formulations to downregulate expression of prdm14 protein
WO2025041340A1 (ja) 二重特異性核酸
WO2025259875A1 (en) Novel antibody oligonucleotide drug conjugates containing gemcitibine for pharmaceutical compositions and related methods of use and treatment
JP2026513654A (ja) メラノサイト性疾患の治療方法
HK40076806A (en) Cancer treatment using targeted sirna pharmaceutical formulations to downregulate expression of prdm14 protein
AU2015221515A1 (en) Organic compositions to treat Beta-ENaC-related diseases